Biography for John Carroll
John D. Carroll,
Editor-in-Chief
John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at [email protected]. Follow @JohnCFierce on Twitter.
Articles by John Carroll
About 2 of every 3 American adults aged 36 to 39 tracked the frenzy of reports that erupted after the swine flu pandemic broke out and concluded that there was something there that was at least...
A new survey out from the CDC demonstrates just how potent a recommendation for vaccinations can be, and how quickly parents can overlook a jab when they aren't being urged repeatedly to provide...
The U.S. Department of Defense has awarded Paragon Bioservices, a contract manufacturing organization, a $15 million contract to develop a mammalian process to manufacture vaccines for filoviruses,...
Inovio Pharmaceuticals' irrepressible Joseph Kim gets the spotlight at U.S. News & World Report, which highlights the company's work on a universal flu vaccine and the CEO's certainty...
A group of European investigators working in league with a small biotech spun out of Merck four years ago has claimed an early-stage success with a small human trial that has generated positive
The prestigious British Medical Journal has put one last nail in the coffin that's been fashioned to bury the professional reputation of Andrew Wakefield, the controversial researcher fingered as the
Novartis has submitted its meningococcal B vaccine Bexsero to the EU for marketing approval. "The Bexsero submission in the EU is an important milestone toward achieving the world's first
Pfizer (
$PFE) has turned to Australia's Phylogica for help in finding a new generation of peptide-based vaccines. In exchange for $500,000 upfront and up to $134 million in milestones, Phylogica will
Novartis blueprints $36M vaccine research lab in NC
Novartis (
$NVS) has blueprinted plans for a $36 million vaccine research lab in Holly Springs, NC, and plans to fill about 100 high-paying jobs to staff the addition. The expansion follows the
The news this week that AstraZeneca (
$AZN) is writing off its big motavizumab program for RSV has shifted the spotlight to a slate of earlier stage compounds as well as vaccines. The Wall Street
